Synergism between fibronectin and transforming growth factor-β1 in the production of substance P in monocytes of patients with myelofibrosis

References

• Rameshwar P, Oh HS, Yook C, . Substance p-fibronectin-cytokine interactions in myeloproliferative disorders with bone marrow fibrosis. Acta Haematol 2003;109:1–10.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011;29:573–582.
   PubMed Web of Science ®Google Scholar
• Hussein K, Theophile K, Dralle W, . MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia. Platelets 2009;20:391–400.
   PubMed Web of Science ®Google Scholar
• Shehata M, Schwarzmeier JD, Hilgarth M, . TGF-b1 induces bone marrow reticulin fibrosis in hairy cell leukemia. J Clin Invest 2004;113:676–685.
   PubMed Web of Science ®Google Scholar
• Rameshwar P, Chang VT, Thacker UF, . Systemic transforming growth factor-beta in patients with bone marrow fibrosis– pathophysiological implications. Am J Hematol 1998;59:133–142.
   PubMed Web of Science ®Google Scholar
• Rameshwar P, Narayanan R, Qian J, . NF-kB as a central mediator in the induction of TGF-b1 in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol 2000;165:2271–2277.
   PubMed Web of Science ®Google Scholar
• Martyre MC, Romquin N, Le Bousse-Kerdiles MC, . Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994;88:9–16.
   PubMed Web of Science ®Google Scholar
• Sato M, Muragaki Y, Saika S, . Targeted disruption of TGF-b1/ Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003;112:1486–1494.
   PubMed Web of Science ®Google Scholar
• Arribillaga L, Dotor J, Basagoiti M, . Therapeutic effect of a peptide inhibitor of TGF-[beta] on pulmonary fibrosis. Cytokine 2011;53:327–333.
   PubMed Web of Science ®Google Scholar
• Komura E, Tonetti C, Penard-Lacronique V, . Role for the nuclear factor kB pathway in transforming growth factor-b1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. Cancer Res 2005;65:3281–3289.
   PubMed Web of Science ®Google Scholar
• Rosenkranz MA. Substance P at the nexus of mind and body in chronic inflammation and affective disorders. Psychol Bull 2007; 133:1007–1037.
   PubMed Web of Science ®Google Scholar
• Joshi DD, Dang A, Yadav P, . Negative feedback on the effects of stem cell factor on hematopoiesis is partly mediated through neutral endopeptidase activity on substance P: a combined functional and proteomic study. Blood 2001;98:2697–2706.
   PubMed Web of Science ®Google Scholar
• Katayama I, Nishioka K. Substance P augments fibrogenic cytokine-induced fibroblast proliferation: possible involvement of neuropeptide in tissue fibrosis. J Dermatol Sci 1997;15:201–206.
   PubMed Web of Science ®Google Scholar
• Munoz M, Covenas R. Neurokinin-1 receptor: a new promising target in the treatment of cancer. Discov Med 2010;10:305–313.
   PubMed Web of Science ®Google Scholar
• Pavlovic S, Liezmann C, Blois SM, . Substance P is a key mediator of stress-induced protection from allergic sensitization via modified antigen presentation. J Immunol 2011;186:848–855.
   PubMedGoogle Scholar
• Vink R, van den Heuvel C. Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury. Neurotherapeutics 2010;7:74–80.
   PubMed Web of Science ®Google Scholar
• Rameshwar P, Joshi DD, Yadav P, . Mimicry between neurokinin-1 and fibronectin may explain the transport and stability of increased substance P immunoreactivity in patients with bone marrow fibrosis. Blood 2001;97:3025–3031.
   PubMed Web of Science ®Google Scholar
• Klassert TE, Patel SA, Rameshwar P. Tachykinins and neurokinin receptors in bone marrow functions: neural-hematopoietic link. J Receptor Ligand Channel Res 2010;2010:51–61.
   PubMedGoogle Scholar
• Nakanishi S. Substance P precursor and kininogen: their structures, gene organizations, and regulation. Physiol Rev 1987;67:1117–1142.
   PubMed Web of Science ®Google Scholar
• Greco SJ, Rameshwar P. MicroRNAs regulate synthesis of the neurotransmitter substance P in human mesenchymal stem cell-derived neuronal cells. Proc Natl Acad Sci USA 2007;104: 15484–15489.
   PubMed Web of Science ®Google Scholar
• Liu K, Castillo MD, Murthy RG, . Tachykinins and hematopoiesis. Clin Chim Acta 2007;385:28–34.
   PubMed Web of Science ®Google Scholar
• Kohara H, Tajima S, Yamamoto M, . Angiogenesis induced by controlled release of neuropeptide substance P. Biomaterials 2010;31:8617–8625.
   PubMed Web of Science ®Google Scholar
• Harrison NK, Dawes KE, Kwon OJ, . Effects of neuropeptides on human lung fibroblast proliferation and chemotaxis. Am J Physiol Lung Cell Mol Physiol 1995;268:L278–L283.
   Google Scholar
• Elliott MA, Verstovsek S, Dingli D, . Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 2007;31:1503–1509.
   PubMed Web of Science ®Google Scholar
• Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999;17:2954–2970.
   PubMed Web of Science ®Google Scholar
• Lim PK, Bliss SA, Patel SA, . Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res 2011;71:1550–1560.
   PubMed Web of Science ®Google Scholar
• Qian J, Yehia G, Molina CA, . Cloning of human preprotachykinin-I promoter and the role of cyclic adenosine 5’-monophosphate response elements in its expression by IL-1 and stem cell factor. J Immunol 2001;166:2553–2561.
   PubMed Web of Science ®Google Scholar
• Rameshwar P, Chang VT, Thacker UF, . Systemic transforming growth factor-beta in patients with bone marrow fibrosis–pathophysiological implications. Am J Hematol 1998;59:133–142.
   PubMed Web of Science ®Google Scholar
• Rameshwar P, Gascon P, Bandari PS, . Structural similarity between the bone marrow extracellular matrix protein and neurokinin 1 could be the limiting factor in the hematopoietic effects of substance P. Can J Physiol Pharmacol 2002;80:475–481.
   PubMed Web of Science ®Google Scholar
• Scherber R, Dueck AC, Johansson P, . The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011;118:401–408.
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Passamonti F, . Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 2012;119:2239–2241.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23:8520–8530.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vaidya R, Caramazza D, . Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356–1363.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Merchant D, Mahmud N, . Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 2007;110:986–993.
   PubMed Web of Science ®Google Scholar
• Greco SJ, Smirnov SV, Murthy RG, . Synergy between the RE-1 silencer of transcription and NFkB in the repression of the neurotransmitter gene TAC1 in human mesenchymal stem cells. J Biol Chem 2007;282:30039–30050.
   PubMed Web of Science ®Google Scholar
• Rameshwar P, Gascon P. Induction of negative hematopoietic regulators by neurokinin-A in bone marrow stroma. Blood 1996;88: 98–106.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vaidya R, Caramazza D, . Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356–1363.
   PubMed Web of Science ®Google Scholar
• Munoz M, Covenas R. NK-1 receptor antagonists: a new paradigm in pharmacological therapy. Curr Med Chem 2011;18:1820–1831.
   PubMed Web of Science ®Google Scholar
• Koon HW, Shih D, Karagiannides I, . Substance P modulates colitis-asscociated fibrosis. Am J Pathol 2010;177:2300–2309.
   PubMed Web of Science ®Google Scholar
• Marriott I, Bost KL. Substance P diminishes lipopolysaccharide and interferon-[gamma]-induced TGF-[beta]1 production by cultured murine macrophages. Cell Immunol 1998;183:113–120.
   PubMed Web of Science ®Google Scholar
• Beinborn M, Blum A, Hang L, . TGF-beta regulates T-cell neurokinin-1 receptor internalization and function. Proc Natl Acad Sci USA 2010;107:4293–4298.
   PubMed Web of Science ®Google Scholar
• Sun J, Ramnath RD, Zhi L, . Substance P enhances NF-kB transactivation and chemokine response in murine macrophages via ERK1/2 and p38 MAPK signaling pathways. Am J Physiol Cell Physiol 2008;294:C1586–C1596.
   PubMed Web of Science ®Google Scholar
• Saban MR, Nguyen NB, Hammond TG, . Gene expression profiling of mouse bladder inflammatory responses to LPS, substance P, and antigen-stimulation. Am J Pathol 2002;160:2095–2110.
   PubMed Web of Science ®Google Scholar
• Marriott I, Mason MJ, Elhofy A, . Substance P activates NF-κB independent of elevations in intracellular calcium in murine macrophages and dendritic cells. J Neuroimmunol 2000;102:163–171.
   PubMed Web of Science ®Google Scholar
• Rameshwar P, Denny TN, Stein D, . Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta. J Immunol 1994;153:2819–2830.
   PubMed Web of Science ®Google Scholar